Precision BioSciences, Inc. (DTIL)
 NASDAQ: DTIL · Real-Time Price · USD
 7.36
 -0.80 (-9.80%)
  At close: Nov 3, 2025, 4:00 PM EST
7.74
 +0.38 (5.16%)
  After-hours: Nov 3, 2025, 4:38 PM EST
Precision BioSciences Revenue
Precision BioSciences had revenue of $13.00K in the quarter ending September 30, 2025, a decrease of -97.74%. This brings the company's revenue in the last twelve months to $698.00K, down -99.07% year-over-year. In the year 2024, Precision BioSciences had annual revenue of $68.70M with 40.98% growth.
Revenue (ttm) 
 $698.00K
Revenue Growth 
 -99.07%
P/S Ratio 
 105.95
Revenue / Employee 
 $6,463
Employees 
 108
Market Cap 
86.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 68.70M | 19.97M | 40.98% | 
| Dec 31, 2023 | 48.73M | 23.63M | 94.15% | 
| Dec 31, 2022 | 25.10M | -90.43M | -78.28% | 
| Dec 31, 2021 | 115.53M | 91.24M | 375.72% | 
| Dec 31, 2020 | 24.29M | 2.05M | 9.20% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| AbbVie | 59.64B | 
| Eli Lilly and Company | 59.42B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
DTIL News
- 18 hours ago - Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
 - 3 days ago - Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025 - Business Wire
 - 20 days ago - Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025 - Business Wire
 - 25 days ago - Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases - Business Wire
 - 27 days ago - Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial - Business Wire
 - 4 weeks ago - Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society - Business Wire
 - 6 weeks ago - Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript - Seeking Alpha
 - 7 weeks ago - Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium - Business Wire